Icon

Icon reports 10% increase in Q1 2012

Wednesday, April 25, 2012 09:45 AM

Icon, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, has released its first quarter financial results for 2012, reporting its Q1 net revenues grew 10% year on year to $252.3 million from $229.3 million in Q1 2011.

More... »

WIRB Copernicus Group

ICON, Roche in technology partnership

Tuesday, March 6, 2012 01:27 PM

Global CRO ICON has been selected by Roche as its technology partner for storing and managing medical images collected during the company’s clinical research programs.

More... »

CRF Health eCOA webinar series

ICON reports quarterly revenue up 5%

Friday, February 17, 2012 01:43 PM

ICON,a global CRO, has reported financial results for the full year and for the fourth quarter ending Dec. 31, 2011.

More... »

Premier Research names Drouet executive director, Oncology Europe

Monday, January 23, 2012 12:36 PM

Premier Research Group has appointed Etienne Drouet executive director, Oncology Europe. Drouet will play a leading role in the operations, strategic planning and corporate development of Premier Research’s growing portfolio of oncology businesses.

More... »

ICON named sole provider of central lab services to Shire

Monday, January 9, 2012 01:45 PM

CRO ICON has signed a strategic partnership with Shire Specialty Pharmaceuticals to serve as the sole global provider of central laboratory services and one of two strategic partners for clinical development services.

More... »

Icon boosts its presence in Asia with acquisition of Chinese CRO BeijingWits Medical Consulting

Monday, December 19, 2011 10:13 AM

Now that many mid-tier CROs have been acquired by either equity investment firms or other CROs and the trend has slowed, a new form of consolidation is emerging. Robust CROs are rounding out their offerings with small but strategic acquisitions to make them bigger, stronger and more complete. The ultimate goal: to continue winning lucrative strategic outsourcing agreements from sponsors.  

More... »

ICON to acquire BeijingWits Medical Consulting

Monday, December 12, 2011 01:21 PM

ICON has agreed, subject to closing conditions, to acquire BeijingWits Medical Consulting, a CRO in China. The transaction is expected to close in the first quarter of 2012.

More... »

Survey: Sponsor’s choice of central lab affects investigator’s satisfaction with trial experience

Monday, December 12, 2011 09:04 AM

The choice of a central lab can greatly affect a principal investigator’s satisfaction level while conducting a clinical trial. 

More... »

Tang joins ICON Development Solutions

Monday, November 28, 2011 11:29 AM

ICON's Development Solutions division has named Dr. Daniel Tang general manager, Asia Pacific. Tang will lead the development of ICON’s early phase activities across the region, including bioanalytical laboratory services, and the development of strong links with key opinion leaders for early phase clinical testing.

More... »

Tasly Pharmaceuticals selects ICON for phase III T89 trial

Monday, November 21, 2011 04:52 PM

ICON has been selected by Tasly Pharmaceuticals for the company’s global phase III T89 trial. T89, also known as Dantonic pill, aims to become the first traditional Chinese medicine to receive FDA approval in the United States. Dantonic pill is a botanical product for the treatment of chronic stable angina pectoris due to coronary heart disease. It is a modernized version of a traditional Chinese herbal medicine and was approved by the State Food and Drug Administration (SFDA) of China in 1993. Since then, more than 2 billion doses have been used by over 10 million patients. 

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs